Alfasigma S.P.A.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
26
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Homogeneous formulation comprising omega-3 polyunsatured fatty acid and resveratrol for oral administration (US 10,300,035) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 2 fees due Dec 6 to 25, 2026 · next Dec 6
- 1 fee due Jan 21, 2027The maintenance fee for Composition useful for the prevention or reduction of the progression of prostate cancer (US 9,084,812) comes due Jan 21, 2027. Unpaid by Jul 21, 2027, it lapses early.
- 1 fee due Feb 13, 2027The maintenance fee for Methods for the Treatment of Cardiovascular Disorders (US 10,376,520) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
- 3 fees due Mar 8 to 12, 2027 · next Mar 8
- 2 fees due Apr 1 to 6, 2027 · next Apr 1
- 2 fees due Jun 3 to 12, 2027 · next Jun 3
- 2 fees due Jul 14 to 19, 2027 · next Jul 14
- 2 fees due Aug 11 to 13, 2027 · next Aug 11
- 1 fee due Sep 15, 2027The maintenance fee for Aminotriazolopyridine for Use in the Treatment of Inflammation, and Pharmaceutical Compositions Thereof (US 9,284,311) comes due Sep 15, 2027. Unpaid by Mar 15, 2028, it lapses early.
- 1 fee due Oct 12, 2027The maintenance fee for Novel Compound Useful for the Treatment of Degenerative and Inflammatory Diseases (US 9,309,244) comes due Oct 12, 2027. Unpaid by Apr 12, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for Pharmaceutical Compositions Comprising a Jak Inhibitor (US 11,975,008) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,842,023 | Container for vial of radiopharmaceutical and set for its infusion in a patient or for its transfer elsewhere In force · From the USPTO record | In force | From the USPTO record | |
| US RE45,968 | Vector for efficient selection and/or maturation of an antibody and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 7,560,485 | Method for treating intermittent claudication comprising the administration of propionyl L-carnitine and a concomitant physical training In force · From the USPTO record | In force | From the USPTO record | |
| US 8,658,671 | Crystalline form of a quinolinone-carboxamide compound In force · From the USPTO record | In force | From the USPTO record | |
| US 10,280,177 | Use of polyols to obtain stable polymorphous forms of rifaximin In force · From the USPTO record | In force | From the USPTO record | |
| US 8,193,196 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations In force · From the USPTO record | In force | From the USPTO record | |
| US RE48,286 | Steroids as agonists for FXR In force · From the USPTO record | In force | From the USPTO record | |
| US 8,217,054 | Use of polyols to obtain stable polymorphous forms of rifaximin In force · From the USPTO record | In force | From the USPTO record | |
| US 7,728,004 | Crystalline Form of a Quinolinone-Carboxamide Compound In force · High confidence | In force | High confidence | |
| US 8,765,778 | Rifamycin derivatives In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 83: 24 lapsed for an unpaid fee · 55 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 9 abandoned · 10 no status recorded